Advertisement

PharmacoEconomics

, Volume 23, Issue 6, pp 567–581 | Cite as

Remission from depression

A Review of venlafaxine clinical and economic evidence
  • Donald Han
  • Edward C. Y. Wang
Review Article

Abstract

Worldwide, major depression is the leading cause of years lived with a disability, and the fourth cause of disability-adjusted life years. Depression is second only to hypertension as the most common chronic condition encountered in general medical practice. Unfortunately, despite the high prevalence of depression, under-recognition and under-treatment are common.

Historically, clinicians have assessed the short-term effectiveness of antidepressants by response rates, often defined as a 50% reduction in depressive symptoms. However, this usually does not reflect true clinical remission, and residual symptoms are common. Persistence of residual symptoms appears to be a common link to relapse, chronic disability and suicide. The burden of not treating depression effectively to remission is significant, as the disease is an important contributor to the disability levels of the general population. Disability, in turn, has a profound impact on lost productivity and medical expenses. In 2000, depression cost the US more than $US83 billion annually in lost productivity, medical expenses and premature death.

Venlafaxine, a dual-acting serotonin norepinephrine (noradrenaline) reuptake inhibitor, may improve a patient’s response to treatment and their chances of achieving complete remission compared with conventional antidepressant therapies, with the evidence for this being the strongest for comparisons with the selective serotonin receptor inhibitors (SSRIs). To date, there are only a small number of economic studies of venlafaxine, and most are cost or resource utilisation analyses with significant limitations. Nevertheless, two cost-effectiveness analyses of venlafaxine are available. They found venlafaxine had a lower average cost per patient achieving remission or per symptom-free day compared with SSRIs; one reported an incremental cost-effectiveness ratio for venlafaxine of $US586 (year 2002 values) per additional patient achieving remission over 8 weeks, and the other found venlafaxine to be a dominant treatment choice over SSRIs over 6 months (year 2001 values). Although requiring further confirmation, these initial data suggest that venlafaxine is a cost-effective strategy for the treatment of depression.

The availability of an effective armamentarium of antidepressant strategies, including venlafaxine, to achieve and sustain remission offers both clinical and economic value to all those touched by the burden of depression.

Keywords

Depressive Symptom Venlafaxine Mirtazapine Antidepressant Therapy Noradrenergic System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Both authors were salaried employees of Wyeth Pharmaceuticals, Ontario, Canada, at the time the review was conducted. Funding for the review was provided by Wyeth Pharmaceuticals, Ontario, Canada.

The authors wish to thank Arnold Seto for his contribution to the construction of the manuscript and Luke Lukic for his review of the manuscript.

References

  1. 1.
    Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003; 12 (1): 3–21PubMedCrossRefGoogle Scholar
  2. 2.
    Davidson JRT, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J Clin Psychiatry 1999; 60 Suppl. 7: 4–9PubMedGoogle Scholar
  3. 3.
    World Health Organization. Adherence to long-term therapies: evidence for action [online]. Available from URL: http://www.who.int/chronic__conditions/en/adherencereport.pdf [Accessed 2003 Aug 13]
  4. 4.
    National Mental Health Association. Co-occurrence of depression with medical, psychiatric, and substance abuse disorders [online]. Available from URL: http://www.nmha.org/infoctr/factsheets/28.cfm [Accessed 2003 Apr 8]
  5. 5.
    Lecrubier Y. Is depression under-recognized and undertreated? Int Clin Psychopharmacol 1998x; 13 Suppl. 5: S3–6PubMedCrossRefGoogle Scholar
  6. 6.
    Lecrubier Y, Hergueta T. Differences between prescription and consumption of antidepressants and anxiolytics. Int Clin Pyschopharmacol 1998; 13 Suppl. 2: S7–S11Google Scholar
  7. 7.
    Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992; 49: 809–16PubMedCrossRefGoogle Scholar
  8. 8.
    Keller MB, Lavori PW, Lewis CE, et al. Predictors of relapse in major depressive disorder. JAMA 1983; 250: 3299–304PubMedCrossRefGoogle Scholar
  9. 9.
    Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157: 22933CrossRefGoogle Scholar
  10. 10.
    Rudolph RL. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2002; (415): 24–30PubMedCrossRefGoogle Scholar
  11. 11.
    Ferrier IN. Treatment of major depression: is improvement enough? J Clin Psychiatry 1999; 60 Suppl. 6: 10–4PubMedGoogle Scholar
  12. 12.
    Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991 Sep; 48 (9): 851–5PubMedCrossRefGoogle Scholar
  13. 13.
    Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000; 157: 1501–4PubMedCrossRefGoogle Scholar
  14. 14.
    Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 2003; 289: 3152–60PubMedCrossRefGoogle Scholar
  15. 15.
    Agency for Health Care Policy and Research. Ethical Practice Guidelines Number 5: Depression in primary care, 2: treatment of major depression. Rockville (MD): Agency for Health Care Policy and Research, US Dept of Health and Human Services, 1993,0551Google Scholar
  16. 16.
    American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder [online]. 2nd rev. ed. Washington, DC, 2000. Available from URL: http://www.psych.org/psych-pract/treatg/pg/Depression2e.book.cfm [Accessed 2004 May 5]Google Scholar
  17. 17.
    Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000; 14: 3–20PubMedCrossRefGoogle Scholar
  18. 18.
    Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments (CANMAT): CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001; 46 Suppl. 1: 5S92SGoogle Scholar
  19. 19.
    Cohen J. Statistical power analysis for the behavioral sciences. Orlando (FL): Academic Press, 1977Google Scholar
  20. 20.
    Anderson I. Meta-analytical studies on new antidepressants. Br Med Bull 2001; 57: 161–78PubMedCrossRefGoogle Scholar
  21. 21.
    Anderson I. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998; 7 Suppl. 1: 11–7PubMedCrossRefGoogle Scholar
  22. 22.
    Anderson I. Selective serotonin reuptake inhibitors versus tricyclic antidepressant: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19–36PubMedCrossRefGoogle Scholar
  23. 23.
    Thase ME, Entusah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234–41PubMedCrossRefGoogle Scholar
  24. 24.
    Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002; 180: 396–404PubMedCrossRefGoogle Scholar
  25. 25.
    Nemeroff CB. COMprehensive Pooled Analysis of Remission (COMPARE) data: venlafaxine vs SSRIs. European College of Neuropsychopharmacology (ECNP); 2003 Sep 20–24; Prague, Czech RepublicGoogle Scholar
  26. 26.
    IMS data [online]. Available from URL: http://www.imsglobal.com/insight/newsstory/0107/newstory-010726a.htm [Accessed 2003 Sep 17]
  27. 27.
    Bula C, Wietlisbach V, Bumand B, et al. Depressive symptoms as a predictor of 6-month outcomes and services utilization in elderly medical inpatients. Arch Intern Med 2001; 161: 260915CrossRefGoogle Scholar
  28. 28.
    Lee Y, Choi K, Lee Y. Association of comorbidity with depressive symptoms in community-dwelling older persons. Gerontology 2001; 47: 254–62PubMedCrossRefGoogle Scholar
  29. 29.
    Pouget R, Yersin B, Wietlisbach V, et al. Depressed mood in a cohort of elderly medical inpatients: prevalence, clinical correlates and recognition rate. Aging (Milano) 2000; 12: 301–7Google Scholar
  30. 30.
    Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58: 844–50PubMedCrossRefGoogle Scholar
  31. 31.
    Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 40518Google Scholar
  32. 32.
    Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003; 64: 1465–75PubMedCrossRefGoogle Scholar
  33. 33.
    Kessler RC, Barber C, Birnbaum HG, et al. Depression in the workplace: effects on short-term disability. Health Aff (Millwood) 1999; 18 (5): 163–71CrossRefGoogle Scholar
  34. 34.
    Simon GE, Katon W, Rutter C, et al. Impact of improved depression treatment in primary care on daily functioning and disability. Psychol Med 1998; 28: 693–701PubMedCrossRefGoogle Scholar
  35. 35.
    Druss BG, Schlesinger M, Allen HM. Depressive symptoms, satisfaction with health care, and 2-year work outcomes in an employed population. Am J Psychiatry 2001; 158 (5): 731–4PubMedCrossRefGoogle Scholar
  36. 36.
    Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression. JAMA 2003 Jun 18; 289 (23): 3135–44PubMedCrossRefGoogle Scholar
  37. 37.
    Simon G, Ormel J, VonKorff M, et al. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995; 152: 352–7PubMedGoogle Scholar
  38. 38.
    Simon G, Von Korff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry 1995; 52: 850–6PubMedCrossRefGoogle Scholar
  39. 39.
    Unutzer J, Patrick DL, Simon G, et al. Depressive symptoms and the cost of health services in HMO patients aged 65 and older: a 4-year prospective study. JAMA 1997; 277 (2): 161823CrossRefGoogle Scholar
  40. 40.
    Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991; 52 Suppl. 5: 28–34PubMedGoogle Scholar
  41. 41.
    Paykel ES. Achieving gains beyond response. Acta Psychiatr Scand 2002; 106 Suppl. 415: 12–7CrossRefGoogle Scholar
  42. 42.
    Bakish D. New standard of depression treatment: remission and full recovery. J Clin Psychiatry 2001; 62 Suppl. 26: 5–9PubMedGoogle Scholar
  43. 43.
    Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998; 59: 608–19PubMedCrossRefGoogle Scholar
  44. 44.
    Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25: 1171–80PubMedCrossRefGoogle Scholar
  45. 45.
    Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry 1992; 149: 104652Google Scholar
  46. 46.
    Barraclough B, Bunch J, Nelson B, et al. A hundred cases of suicide: clinical aspects. Br J Psychiatry 1974; 125: 355–73PubMedCrossRefGoogle Scholar
  47. 47.
    Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behaviour. J Affect Disord 1982; 4: 291–8PubMedCrossRefGoogle Scholar
  48. 48.
    Thase ME. The clinical, psychosocial, and pharmacoeconomic ramifications of remission. Am J Managed Care 2001; 7 (11): S377–85Google Scholar
  49. 49.
    Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998; 55: 694–700PubMedCrossRefGoogle Scholar
  50. 50.
    Zis AP, Grof P, Webster M, et al. Prediction of relapse in recurrent affective disorder. Psychopharmacol Bull 1980; 16 (1): 47–9PubMedGoogle Scholar
  51. 51.
    Roy-Byrne P, Post RM, Uhde TW, et al. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl 1985; 317: 1–34PubMedCrossRefGoogle Scholar
  52. 52.
    Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998 Dec; 55 (12): 1128–32PubMedCrossRefGoogle Scholar
  53. 53.
    Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000 May-Jun; 22 (3): 153–62PubMedCrossRefGoogle Scholar
  54. 54.
    Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol 1996; 16 (3 Suppl. 2): 1S–9S)PubMedCrossRefGoogle Scholar
  55. 55.
    Thase ME. Antidepressant options: venlafaxine in perspective. J Clin Psychopharmacol 1996; 16 (3 Suppl. 2): 1 OS–20SGoogle Scholar
  56. 56.
    Barbui C, Hotopf M. Amitriptyline vs the rest: still the leading antidepressant after 40 years of randomized controlled trials. Br J Psychiatry 2001; 178: 129–44PubMedCrossRefGoogle Scholar
  57. 57.
    Danish University Antidepressant Group. Citalopram: Clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology 1986; 90: 131–8Google Scholar
  58. 58.
    Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990; 18: 289–309CrossRefGoogle Scholar
  59. 59.
    Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 911–8PubMedCrossRefGoogle Scholar
  60. 60.
    Simon IS, Agviar LM, Kunz NR, et al. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res 2004; 38: 249–57PubMedCrossRefGoogle Scholar
  61. 61.
    Montgomery SA, Entsuah R, Hackett D, et al. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry 2004; 65 (3): 328–36PubMedCrossRefGoogle Scholar
  62. 62.
    Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994; 9: 139–43PubMedCrossRefGoogle Scholar
  63. 63.
    Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 57–71PubMedCrossRefGoogle Scholar
  64. 64.
    Silverstone PH, Ravindran A, for the Venlafaxine XR 360 Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999; 60: 22–8PubMedCrossRefGoogle Scholar
  65. 65.
    Rudolph RL, Feiger AD. A double-blind, randomized, placebocontrolled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999; 56: 171–81PubMedCrossRefGoogle Scholar
  66. 66.
    Rudolph RL, Entsuah R, Agviar L. Early onset of anitdepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study [abstract]. Fur Neuropsychopharmacol 1998; 8 (Suppl. 2): S142CrossRefGoogle Scholar
  67. 67.
    Salinas E, for the Venlafaxine XR 367 Study Group. Once-daily venlafaxine extended release XR venlafaxine versus paroxetine in outpatients with major depression [abstract]. Biol Psychiatry 1997; 42 Suppl. 1: 244SGoogle Scholar
  68. 68.
    Study 347 and 349. Wyeth Pharmaceuticals, 2004 (Data on file)Google Scholar
  69. 69.
    Kroenke K. Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res 2003; 12 (1): 34–43PubMedCrossRefGoogle Scholar
  70. 70.
    Entsuah R. Venlafaxine vs SSRIs: comparison of Somatic Symptom Resolution [abstract]. European College of Neuropsychopharmacology (ECNP); 2003 Sep 20–24; Prague, Czech RepublicGoogle Scholar
  71. 71.
    Kunz N, Lenox-Smith A, Entsuah R. Use of venlafaxine for chronic pain associated with postherpetic neuralgia [abstract]. British Association for Psychopharmacology; 2003 Jul 20–23; Cambridge, UKGoogle Scholar
  72. 72.
    Entsuah R, Sawyer P, Willard L. Symptomatic improvement in depression: venlafaxine vs SSRIs [abstract]. British Association for Psychopharmacology; 2003 Jul 20–23; Cambridge, UKGoogle Scholar
  73. 73.
    Trivedi M, Wan GJ, Mallick R, et al. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. J Clin Psychopharmacol 2004; 24 (5): 497–506PubMedCrossRefGoogle Scholar
  74. 74.
    Wan GJ, Crown WH, Berndt ER, et al. Health and productivity costs of depression treatment with venlafaxine extended-release and SSRIs [abstract]. Institute of Health and Productivity Management 2nd Annual Conference; 2002 Sep 24–26; Scottsdale (AZ)Google Scholar
  75. 75.
    Wan GJ, Crown WH, Berndt ER, et al. Health care expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety. Int J Clin Pract 2002; 56: 434–9PubMedGoogle Scholar
  76. 76.
    Hamed A, Ren XS, Lee A, et al. SNRI associated with more reductions in the number of outpatient psychiatric visits compared with SSRIs or TCAs [abstract]. College of International Neuropsychopharmacology Meeting; 2002 Jun 23–27; Montreal (QC), CanadaGoogle Scholar
  77. 77.
    Monfared A, Sheehy O, Han D, et al. Assessment of provincial expenditures in depressed patients treated with venlafaxine XR vs SSRIs (APEX Study) [abstract]. Canadian Association for Population Therapeutics Conference; 2005 Apr 17–19; Vancouver (BC)Google Scholar
  78. 78.
    Lenox-Smith A, Conway P, Knight C. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. Pharmacoeconomics 2004; 22 (5): 311–9PubMedCrossRefGoogle Scholar
  79. 79.
    Mallick R, Chen J, Entsuah R. Work impairment associated with depression: a pooled analysis of venlafaxine compared with SSRIs and placebo. Poster presented at the European Congress of the World Psychiatric Association; 2001 Sep 30Oct 4; Madrid, SpainGoogle Scholar
  80. 80.
    Baker CB, Woods SW. Cost of treatment failure for major depression: direct costs of continued treatment. Adm Policy Ment Health 2001 Mar; 28 (4): 263–77PubMedCrossRefGoogle Scholar
  81. 81.
    Murray CJL, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge (MA): Harvard University Press, 1996Google Scholar
  82. 82.
    Pharmaceutical Research and Manufacturers of America. How much do managed care companies spend on prescription medicines? Washington, DC: PhRMA, 2003Google Scholar
  83. 83.
    Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001; 62: 869–77PubMedCrossRefGoogle Scholar
  84. 84.
    Kennedy S, McIntyre R, Fallu A, et al. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci 2002; 27 (4): 269–80PubMedGoogle Scholar
  85. 85.
    Rizzo JA, Abbott TA, Pashko S. Labour productivity effects of prescribed medicines for chronically ill workers. Health Econ 1996; 5: 249–65PubMedCrossRefGoogle Scholar
  86. 86.
    Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff (Millwood) 2001; 20 (5): 241–51CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Wyeth PharmaceuticalsMarkhamCanada
  2. 2.Cephalon, Inc.FrazerUSA

Personalised recommendations